Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

<p>We listened to <a href="https://www.smartkarma.com/entities/23716" target="_blank" data-smartkarma-citation="entities:23716:1">Cerecor Inc (CERC US)</a> management's conference call (<a href="http://ir.cerecor.com/ir-calendar/detail/756/topline-phase-2-results-for-cerc-301s-phase-2-trial-in" target="_blank">link</a>) about the phase 2 results of CERC-301 as adjunct therapy in major depressive disorder, MDD (<a href="http://ir.cerecor.com/press-releases/detail/30/cerecor-reports-top-line-data-from-cerc-301-phase-2-study" target="_blank">link to press release</a>). On closely analyzing the study data, we agree with the management's assessment that the antidepressant effect of the drug is more prominent at day 2 after oral administration and wears off slightly by day 4. We also agree that in future planned studies, the 20 mg dose of the drug may need to be given twice…</p>

We listened to Cerecor Inc (CERC US) management's conference call (link) about the phase 2 results of CERC-301 as adjunct therapy in major depressive disorder, MDD (link to press release). On closely analyzing the study data, we agree with the management's assessment that the antidepressant effect of the drug is more prominent at day 2 after oral administration and wears off slightly by day 4. We also agree that in future planned studies, the 20 mg dose of the drug may need to be given twice…

Cerecor's Novel Drugs for Major Depression. 'Failed' Trial or Buying Opportunity in the Stock?

United States

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Acadia Pharmaceuticals (ACAD US)

Cerecor's Novel Drugs for Major Depression. 'Failed' Trial or Buying Opportunity in the Stock?

We listened to Cerecor Inc (CERC US) management's conference call (link) about the phase 2 results of CERC-301 as adjunct therapy in major...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)